Art

J-GLOBAL ID：201702210607395138   Reference number：17A0953200

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy

定位放射線手術および抗PD-1療法,抗CTLA-4療法,BRAF/MEK阻害剤,BRAF阻害剤,または従来の化学療法で治療した黒色腫脳転移の臨床転帰

Author (19)： AHMED K. A. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  ABUODEH Y. A. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  ECHEVARRIA M. I. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  ARRINGTON J. A. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  STALLWORTH D. G. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  HOGUE C. (Univ. Louisville, Louisville) ,  NAGHAVI A. O. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  KIM S. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  KIM Y. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  PATEL B. G. (Univ. South Florida, Tampa) ,  SARANGKASIRI S. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  JOHNSTONE P. A. S. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  SAHEBJAM S. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  KHUSHALANI N. I. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  FORSYTH P. A. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  HARRISON L. B. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  YU M. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  ETAME A. B. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa) ,  CAUDELL J. J. (H. Lee Moffitt Cancer Center and Res. Inst., Tampa)
Material： Annals of Oncology  (Ann Oncol)
Volume： 27  Issue： 12  Page： 2288-2294  Publication year： Dec. 2016 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *Stereotactic radiosurgery ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0953200&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (2)： Tumors(=neoplasms)of nervous system  (GN04000V) ,  Treatment for tumors in general  (GE03031L)

Reference (24)：

• Davies MA, Liu P, McIntyre S et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117: 1687-1696.
• Sperduto PW, Chao ST, Sneed PK et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77: 655-661.
• Weber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384.
• Long GV, Stroyakovskiy D, Gogas H et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386: 444-451.
• Long GV, Trefzer U, Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 1087-1095.

Terms in the title (12)： 定位放射線手術 ,  PD-1 ,  療法 ,  CTLA-4 ,  BRAF ,  MEK阻害剤 ,  BRAF阻害剤 ,  化学療法 ,  治療 ,  黒色腫 ,  脳転移 ,  臨床転帰